Shionogi & Co., Ltd. (SGIOF)
OTCMKTS
· Delayed Price · Currency is USD
12.28
+0.07 (0.57%)
At close: Jan 2, 2025
Shionogi & Revenue
Shionogi & had revenue of 116.38B JPY in the quarter ending September 30, 2024, a decrease of -4.00%. This brings the company's revenue in the last twelve months to 418.51B, down -17.36% year-over-year. In the fiscal year ending March 31, 2024, Shionogi & had annual revenue of 435.08B with 1.97% growth.
Revenue (ttm)
418.51B JPY
Revenue Growth
-17.36%
P/S Ratio
n/a
Revenue / Employee
84.39M JPY
Employees
4,959
Market Cap
11.95B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 435.08B | 8.40B | 1.97% |
Mar 31, 2023 | 426.68B | 91.55B | 27.32% |
Mar 31, 2022 | 335.14B | 37.96B | 12.77% |
Mar 31, 2021 | 297.18B | -36.19B | -10.86% |
Mar 31, 2020 | 333.37B | -30.35B | -8.34% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
Veradigm | 1.53B |
SS Innovations International | 16.04M |
Elite Pharmaceuticals | 71.17M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 21.77M |
Jun An Kang Group | 4.47M |
Shionogi & News
- 2 months ago - Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Antibiotics, an important but tricky business, says Shionogi CEO [Advocacy Lab Content] - EURACTIV.com
- 6 months ago - Shionogi & Co., Ltd. (SGIOY) Q1 2024 Earnings Call Transcript - Seeking Alpha
- 8 months ago - Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease - Business Wire
- 1 year ago - Shionogi & Co., Ltd. (SGIOF) Q2 2023 Earnings Conference Call Transcript - Seeking Alpha
- 1 year ago - Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript - Seeking Alpha
- 2 years ago - Shionogi: Likely The Last Viable COVID Play - Seeking Alpha
- 2 years ago - Shionogi & Co., Ltd. (SGIOF) Q3 2022 Earnings Call Transcript - Seeking Alpha